News - Page 9 of 12 - Leukaemia Care

11th December 2018

Axicabtegene ciloleucel approved by NICE

Today, the National Institute for Health and Care Excellence (NICE) has approved the use of axicabtagene ciloleucel (brand name Yescarta) to be funded for use on the NHS in England. It will be available for patients with diffuse large B-cell lymphoma (DLBCL) and primary mestinal B-cell lymphoma (PMBL), after they have tried two other systemic therapies.

5th November 2018

Celebrity christmas card auction goes live!

A unique chance to own some fantastic autographs!

2nd November 2018

GBW hosts a bake-off for Leukaemia Care

Midlands marketing agency Gough Bailey Wright (GBW) has raised over £100 for Leukaemia Care, by hosting its annual bake sale.

5th October 2018

Leukaemia Care response: gemtuzumab ozogamicin

The National Institute of Health and Care Excellence (NICE) have today recommended the use of gemtuzumab ozogamicin to treat previously untreated CD33 positive acute myeloid leukaemia (AML), except for acute promyelocytic leukaemia (APL or APML).

4th October 2018

Liverpool band to head up Leukaemia fundraising gig at world famous cavern club

Championed by BBC Introducing in Merseyside, The Ambitionhave been announced as the headline act for a Cavern Club fundraiser that is set to raise thousands for a national blood cancer charity.

5th September 2018

Leukaemia Care response to NHS England CAR-T announcement:

NHS England Chief Executive Simon Stevens has announced today that children and young people in England will receive a groundbreaking cancer treatment, the first in what is expected to be a rapidly expanding class of personalised cancer therapies available on the NHS.

1st September 2018

A new poll looking at leukaemia awareness in Great Britain has revealed that men are almost twice as likely not to recognise leukaemia as a cancer compared to women

Over one in ten men (11%) had not heard of leukaemia, compared to 6% of women. Moreover, 14% of men were unaware that the disease was a cancer, compared to 8% of women.

9th August 2018

Inotuzumab ozogamicin recommended for acute lymphoblastic leukaemia (ALL) patients

NICE have today recommended the use of inotuzumab ozogamicin to treat relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL) in adults.

9th August 2018

NHS England removes restrictions that were preventing relapsed CLL patients from gaining access to ibrutinib

Today (9th August 2018) NHS England removes restrictions that had been preventing relapsed chronic lymphocytic leukaemia patients from getting treatment with ibrutinib a NICE approved therapy.

20th July 2018

School raise over £750 for Leukaemia Care

A bunch of students from Cradley Heath raise over £750 for Leukaemia Care!